May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Efficacy of Cyclosporine a for the Treatment of Ocular Rosacea
Author Affiliations & Notes
  • J.R. Wittpenn
    Private Practice, Stony Brook, NY
  • B. Schechter
    Rand Eye Institute, Pompano Beach, FL
  • Footnotes
    Commercial Relationships  J.R. Wittpenn, Allergan C; B. Schechter, Allergan C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2846. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.R. Wittpenn, B. Schechter; Efficacy of Cyclosporine a for the Treatment of Ocular Rosacea . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2846.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To compare the efficacy of cyclosporine A (Restasis, Allergan) with an artificial tear solution (Refresh Endura, Allergan) for the treatment of rosacea–associated lid and corneal changes. Methods: Double–masked clinical trial. Patients (n=20) with rosacea–associated lid and corneal changes were enrolled after any active infections were treated with lid scrubs and antibiotics. Once the infection was clinically controlled, patients were randomized to CsA or artificial tears for 3 months. All patients were withdrawn from oral doxycycline for at least 2 weeks and patients with lid defects and lagophthalmos were excluded. Results: Topical CsA produced a statistically significant increase in Schirmer’s (with anesthesia) scores of 2.9 mm after 3 months of treatment (P=.002). Conversely, Schirmer’s scores worsened significantly in the tears group, with a mean decrease of 6.4 mm (P=.029). Similarly, the mean TBUT score also significantly improved in the CsA–treated patients (a mean increase of 3.0 sec, P=.002), but worsened in the control group (a mean decrease of 1.0 sec, P=.319). Moreover, CsA provided significantly greater improvement in OSDI scores than did tears (mean reduction of 9.0 with CsA versus a mean increase of 2.7 with tears, P=.003). Conclusions: Topical cyclosporine A is superior to artificial tears for the treatment of rosacea–associated lid and corneal changes. These findings are currently being confirmed in a larger ongoing clinical trial.

Keywords: autoimmune disease • eyelid • cornea: tears/tear film/dry eye 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×